An investigation for investors in NASDAQ:CYCC shares was announced over potential breaches of fiduciary duties by certain officers and directors at Cyclacel Pharmaceuticals.
Investors who purchased shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) and currently hold any of those NASDAQ:CYCC shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Cyclacel Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
Berkeley Heights, NJ based Cyclacel Pharmaceuticals, Inc. develops therapies that harness the power of the immune system to treat cancer and other serious illnesse. Cyclacel Pharmaceuticals Inc reported that its annual Total Revenue rose from $1.08 million in 2013 to $1.73 million in 2014 while its Net Loss increased from $10.15 million in 2013 to $19.39 million in 2014. Shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) declined from $7.17 per share in November 2012 to as low as $0.30 per share on January 19, 2016.
On March 23, 2016, NASDAQ:CYCC shares closed at $0.411 per share.
Those who purchased NASDAQ:CYCC shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com